Abbott acquires Kalila Medical, expands heart rhythm disorder portfolio

Abbott announced on Feb. 2 that it acquired Kalila Medical, a privately held company that develops medical devices to treat atrial fibrillation and other heart rhythm disorders. Terms of the deal were not disclosed.

In 2014, the FDA granted Kalila Medical 510(k) clearance for its steerable introducer sheath that helps physicians access and perform catheter-based electrophysiology procedures.

Abbott has recently been expanding its atrial fibrillation business, including the 2014 acquisition of Topera, a company that develops electrophysiology technologies to diagnose and treat patients with atrial fibrillation. In January 2016, Abbott released a software update to provide enhanced rotor visualization for serious heart rhythm disorders.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.